A large-scale study of over 246,000 U.S. adults diagnosed with atherosclerotic heart disease reveals that the shingles vaccine significantly reduces cardiovascular risk. The research, presented at an upcoming medical conference, shows a nearly 46% lower likelihood of major adverse cardiac events among vaccinated individuals. This finding adds to mounting evidence that the vaccine offers health benefits beyond preventing the painful shingles rash itself, potentially including protection against heart disease and even dementia.
Why This Matters: Beyond Shingles Prevention
For years, the shingles vaccine has been recommended for adults 50+ (and those with weakened immune systems) to combat herpes zoster – the reactivation of the chickenpox virus. However, emerging research suggests a far broader protective effect. Shingles infections have been linked to increased blood clot formation, raising the risk of heart attacks and strokes. By preventing shingles, the vaccine may indirectly reduce these dangerous events.
The study’s implications are substantial: a nearly half reduction in heart risk is comparable to the benefits of quitting smoking, according to lead author Dr. Robert Nguyen of the University of California, Riverside. This suggests that the vaccine could be a powerful tool in preventing cardiovascular events, particularly for high-risk populations.
Key Findings: A Deep Dive into the Data
Researchers analyzed data from TriNetX, a database containing medical records from millions of Americans between 2018 and 2025. The study compared 123,411 vaccinated adults (who received Shingrix or Zostavax) with an equal number who remained unvaccinated. Both groups were matched for demographics and pre-existing health conditions to ensure fair comparison.
Results showed significant risk reductions in vaccinated individuals:
- 32% lower risk of heart attack
- 25% lower risk of stroke
- 25% lower risk of heart failure
- 66% lower risk of all-cause mortality
These findings suggest the vaccine’s protective effect extends beyond merely preventing the shingles rash. The observed benefits could be due to its ability to reduce inflammation and clotting risks associated with shingles infections.
Long-Term Outlook and Limitations
While the analysis focused on outcomes within one year of vaccination, previous research indicates long-lasting effects. A 2025 study found a 23% reduction in cardiovascular events in healthy adults, with benefits persisting up to eight years.
Researchers acknowledge that vaccination status may correlate with healthier lifestyle choices. While statistical adjustments were made for socioeconomic factors, it’s possible some observed benefits stem from broader health behaviors among vaccinated individuals. Despite this limitation, the study’s large sample size provides strong evidence supporting the vaccine’s heart-protective effect.
“Vaccines are one of the most important medicines we have to prevent disease,” Dr. Nguyen stated. “These results provide another reason for them to elect to get the vaccine.”
The study, titled “Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease,” will be presented on March 30th, reinforcing the importance of vaccination as a key component of heart health.
In conclusion: The evidence continues to build that the shingles vaccine offers substantial cardiovascular benefits. The findings strengthen current recommendations for adults over 50 to receive the vaccine, potentially saving lives and reducing the burden of heart disease.
